Ian Clark has served as a member of the board of directors for Guardant Health since December 2016. Mr. Clark currently serves as Guardant’s Lead Independent Director and serves on the boards of directors of Corvus Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc. and other privately-held companies, including Forty Seven, Inc. He is also a member of Forty Seven, Inc.’s audit committee, and he served on the board of directors and audit committee of Kite Pharma, Inc. from January 2017 to October 2017. He served as Chief Executive Officer of Genentech Inc., or Genentech, from January 2010 to December 2016. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group, or Roche, from April 2009 to December 2009. Prior to his time at Roche, Mr. Clark held several senior management positions at Genentech from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Inc. and Sanofi S.A. in the United Kingdom, France and Eastern Europe. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. Mr. Clark received a B.S. degree in biology from South Hampton University.
What is Ian T. Clark's net worth?
The estimated net worth of Ian T. Clark is at least $1.01 million as of December 5th, 2025. Mr. Clark owns 9,851 shares of Guardant Health stock worth more than $1,011,402 as of December 16th. This net worth estimate does not reflect any other assets that Mr. Clark may own. Learn More about Ian T. Clark's net worth.
How do I contact Ian T. Clark?
Has Ian T. Clark been buying or selling shares of Guardant Health?
During the last quarter, Ian T. Clark has sold $3,066,813.09 in Guardant Health stock. Most recently, Ian T. Clark sold 28,611 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $107.19, for a transaction totalling $3,066,813.09. Following the completion of the sale, the director now directly owns 9,851 shares of the company's stock, valued at $1,055,928.69. Learn More on Ian T. Clark's trading history.
Who are Guardant Health's active insiders?
Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Terilyn Monroe (Insider), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?
During the last year, insiders at the sold shares 39 times. They sold a total of 975,960 shares worth more than $69,608,350.81. The most recent insider tranaction occured on December, 8th when CEO Amirali Talasaz sold 100,000 shares worth more than $10,505,000.00. Insiders at Guardant Health own 6.1% of the company.
Learn More about insider trades at Guardant Health. Information on this page was last updated on 12/8/2025.